These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14529980)

  • 21. Regional differences of melphalan lung levels after isolated lung perfusion in the rat.
    Romijn S; Hendriks JM; Van Putte BP; Weyler J; Guetens G; De Boeck G; Van Schil PE
    J Surg Res; 2005 May; 125(2):157-60. PubMed ID: 15854668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine.
    Rodenbach M; Eyol E; Seelig MH; Berger MR
    J Cancer Res Clin Oncol; 2005 May; 131(5):289-99. PubMed ID: 15657768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
    Shamseddine AI; Khalifeh MJ; Mourad FH; Chehal AA; Al-Kutoubi A; Abbas J; Habbal MZ; Malaeb LA; Bikhazi AB
    Clin Pharmacokinet; 2005; 44(9):957-67. PubMed ID: 16122282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer.
    Maffezzini M; Campodonico F; Puntoni M; Martelli A; Mattioli F
    Urology; 2009 Nov; 74(5):1078-83. PubMed ID: 19773039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy.
    Pestieau SR; Schnake KJ; Stuart OA; Sugarbaker PH
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):269-76. PubMed ID: 11320672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine and the blood brain barrier.
    Davis JR; Fernandes C; Zalcberg JR
    Aust N Z J Med; 1999 Dec; 29(6):831-2. PubMed ID: 10677133
    [No Abstract]   [Full Text] [Related]  

  • 27. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
    Veerman G; Ruiz van Haperen VW; Vermorken JB; Noordhuis P; Braakhuis BJ; Pinedo HM; Peters GJ
    Cancer Chemother Pharmacol; 1996; 38(4):335-42. PubMed ID: 8674156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eradication of osteosarcoma lung metastasis using intranasal gemcitabine.
    Jia SF; Worth LL; Turan M; Duan Xp XP; Kleinerman ES
    Anticancer Drugs; 2002 Feb; 13(2):155-61. PubMed ID: 11901308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regional chemotherapy via pulmonary artery with blood flow occlusion in a solitary tumor nodule model.
    Wang HY; Hochwald S; Ng B; Burt M
    Anticancer Res; 1996; 16(6B):3749-53. PubMed ID: 9042252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    Mercier C; Dahan L; Ouafik L; André N; Ciccolini J
    Eur J Clin Pharmacol; 2010 Sep; 66(9):959-60. PubMed ID: 20563566
    [No Abstract]   [Full Text] [Related]  

  • 31. Isolated lung perfusion with melphalan prolongs survival in a rat model of metastatic pulmonary adenocarcinoma.
    Hendriks JM; Van Schil PE; Van Oosterom AA; Kuppen PJ; Van Marck E; Eyskens E
    Eur Surg Res; 1999; 31(3):267-71. PubMed ID: 10352355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
    Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical development in gemcitabine and its clinical pharmacological profile].
    Tsukagoshi S; Taguchi T
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):877-83. PubMed ID: 10396313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis.
    Apparaju SK; Gudelsky GA; Desai PB
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):223-9. PubMed ID: 17443325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival.
    Port JL; Ng B; Ellis JL; Nawata S; Lenert JT; Burt ME
    Ann Thorac Surg; 1996 Sep; 62(3):848-52. PubMed ID: 8784018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
    Beumer JH; Eiseman JL; Parise RA; Joseph E; Covey JM; Egorin MJ
    Clin Cancer Res; 2008 Jun; 14(11):3529-35. PubMed ID: 18519786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence.
    Seelig MH; Leible M; Sänger J; Berger MR
    Oncol Rep; 2004 May; 11(5):1107-13. PubMed ID: 15069554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
    Tempero M; Plunkett W; Ruiz Van Haperen V; Hainsworth J; Hochster H; Lenzi R; Abbruzzese J
    J Clin Oncol; 2003 Sep; 21(18):3402-8. PubMed ID: 12885837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial.
    Simon N; Romano O; Michel P; Pinçon C; Vasseur M; Lemahieu N; Barthélémy C; Hebbar M; Décaudin B; Odou P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):865-71. PubMed ID: 26193987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
    Marangon E; Sala F; Caffo O; Galligioni E; D'Incalci M; Zucchetti M
    J Mass Spectrom; 2008 Feb; 43(2):216-23. PubMed ID: 17941128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.